Skip to main content
OpenTrials
Completed

NCT Number: NCT00367445

A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Pfizer Investigational Site

Chula Vista, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diabetes mellitus Type 2

Exclusion criteria

  • Severe Asthma, severe COPD
  • Smoking

Treatment and study plan

Inhaled Human Insulin (Exubera)

Drug

Insulin Glargine (Lantus)

Drug

Primary outcomes

  1. Variability of blood glucose over a period of 72 hours

Secondary outcomes

  1. Insulin pharmacokinetics

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A 1 Month, Open-Label Inpatient, Randomized Cross-Over Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On 24-Hour Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Oral Agents

Important dates

Study start
2006
Study completion
2007
First posted
Aug 22, 2006
Registry last updated
Jan 29, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.